Tiziana Life Sciences plc TLSA 深 沪
等待开盘 10-11 09:30:00 美东时间
2.04
-0.090
-4.23%
华盛通- 最 高2.245
- 今 开2.16
- 成交量 41.06万股
- 最 低 1.95
- 昨 收 2.13
- 总市值 2.39亿
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 0.6295
- 委 比 59.36%
- 总股本 1.17亿
- 历史最高 12.15
- 量 比 2.14
- 振 幅 13.85%
- 历史最低 0.41
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence
Tiziana Life Sciences ( ($TLSA) ) has issued an update. On October 3, 2025, Tiz...
10-04 05:04
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
Tiziana Life Sciences announced plans to advance TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R, while continuing to develop its lead intranasal foralumab program. TZLS-501 inhibits IL-6R signaling and reduces IL-6 cytokines, potentially treating inflammation, lung damage, and fibrosis. The company aims to explore non-dilutive funding for TZLS-501 without diverting resources...
09-25 12:30
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
Tiziana Life Sciences will present a scientific poster at the 41st ECTRIMS Congress in Barcelona, detailing the Phase 2a trial design of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). Foralumab, the first fully human anti-CD3 monoclonal antibody for intranasal delivery, aims to modulate the immune system for MS treatment. The trial is expected to provide important insights into novel therapies for this pat...
09-24 12:30
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
Tiziana Life Sciences has received a U.S. Department of Defense grant to study its intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI), targeting acute and chronic phases. The funding aims to expand the therapy's potential beyond autoimmune diseases. SCI affects nearly 300,000 Americans, with no approved treatments improving recovery. Preclinical results show promise in motor outcomes and reducing inflammation. The non-invasive the...
09-15 12:00
Tiziana Life Sciences Chairman Gabriele Cerrone Buys 25K Shares At $1.60; Now Holds 36.28% Of Issued Capital
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,
09-05 20:35
Tiziana Life Sciences Announces Purchase of Shares by Chairman
**Tiziana Life Sciences创始人增持股份，Foralumab临床试验进展顺利** Tiziana Life Sciences创始人Gabriele Cerrone增持25,000股，持股比例增至36.28%。公司核心产品Foralumab作为全球唯一在研的全人源抗CD3单抗，在治疗非活动性继发进展型多发性硬化症的临床试验中表现出色。
09-05 12:30
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences has initiated a Phase 2a trial for its intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease. The study, conducted at Brigham and Women’s Hospital, aims to assess the therapy's potential to reduce neuroinflammation and slow disease progression by targeting regulatory T cells. MSA affects 15,000–50,000 people in the U.S., with no approved treatments to alter its course. Foraluma...
08-14 12:30
Tiziana to begin testing foralumab in multiple system atrophy
Shares of Tiziana Life Sciences (NASDAQ:TLSA) rose after the FDA approved the mid-stage trial initiation of its lead candidate, intranasal foralumab, in patients with multiple system atrophy. The stoc...
08-11 21:29
FDA Approves Tiziana Life Sciences’ Phase 2a Trial for MSA
An update from Tiziana Life Sciences ( ($TLSA) ) is now available. On August 11...
08-11 21:28
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences announced FDA approval of the IND for its Phase 2a trial of intranasal foralumab for Multiple System Atrophy (MSA), a rare, untreatable neurodegenerative disease. The trial will assess the safety and effects of foralumab, a fully human anti-CD3 monoclonal antibody, on microglial activation and clinical outcomes in MSA patients. MSA, with a prevalence of 1.9-4.9 per 100,000 worldwide, causes rapid progression of autonomic and...
08-11 13:00
